Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atricure Inc (NQ: ATRC )

33.51 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atricure Inc

< Previous 1 2 3 4 5 Next >
Earnings Scheduled For February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
Via Benzinga
A Preview Of AtriCure's Earnings
AtriCure (NASDAQ:ATRC) is set to give its latest quarterly earnings report on Tuesday, 2022-02-15. Here's what investors need to know before the announcement. Analysts estimate that AtriCure will... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
AtriCure Publishes Inaugural ESG Report
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Fourth Quarter and Full Year 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2021, Provides Financial Outlook for 2022
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in the 40th Annual J.P. Morgan Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate in Upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference
From AtriCure, Inc.
Via Business Wire
AtriCure, inc (ATRC) Q3 2021 Earnings Call Transcript
ATRC earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AtriCure Reports Third Quarter 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
AtriCure to Participate in Upcoming Investor Conferences
From AtriCure, Inc.
Via Business Wire
AtriCure to Announce Third Quarter 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
AtriCure to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference
From AtriCure, Inc.
Via Business Wire
Return on Capital Employed Insights for AtriCure
After pulling data from Benzinga Pro it seems like during Q2, AtriCure's (NASDAQ:ATRC) reported sales totaled $71.38 million. Despite a 5.09% in earnings, the company posted a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ: 
Via Benzinga
AtriCure, inc (ATRC) Q2 2021 Earnings Call Transcript
ATRC earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
AtriCure Reports Second Quarter 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
AtriCure to Participate at the Canaccord 41st Annual Growth Conference
From AtriCure, Inc.
Via Business Wire
The Daily Biotech Pulse: Equillium Issues Positive Regulatory Update, Biogen In-Licenses Multiple Sclerosis Drug, Aridis Releases COVID-19 Antibody Cocktail Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 12) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
AtriCure to Announce Second Quarter 2021 Financial Results
From AtriCure, Inc.
Via Business Wire
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
AtriCure Names Two New Members to the Board of Directors
From AtriCure, Inc.
Via Business Wire
Expert Ratings for AtriCure
Analysts have provided the following ratings for AtriCure (NASDAQ:ATRC) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2 0 0... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.